cis-2,4-Di-tert-butyl-1,3-dioxolane | 26563-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: cis-2,4-Di-tert-butyl-1,3-dioxolane
• 英文别名: 2,4-ditert-butyl-1,3-dioxolane
• CAS: 26563-86-0
• 化学式: C₁₁H₂₂O₂
• 分子量: 186.29
• InChiKey: WENPMVZGWLEFAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Topical delivery of codrugs
  申请人：Walters A. Kenneth

  公开号：US20080107720A1

  公开（公告）日：2008-05-08

  The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same as, or different from, the first constituent moiety. The first and second constituent moieties are so linked that they are easily transported into or across the dermis, into the skin, or into the blood or lymphatic system, and are reconstituted in vivo to form the first and second constituent moieties.
• Laulimalide Analogues as Therapeutic Agents
  申请人：Wender Paul A.

  公开号：US20080280973A1

  公开（公告）日：2008-11-13

  Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.
• NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS
  申请人：WENDER PAUL A.

  公开号：US20090099252A1

  公开（公告）日：2009-04-16

  Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.
• POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS
  申请人：Ashton Paul

  公开号：US20120195934A1

  公开（公告）日：2012-08-02

  Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.